CureVac
- Country
- Ownership
- -
- Employees
- 1.1K
- Market Cap
- -
- Introduction
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
RNActive® Rabies Vaccine (CV7201) in Healthy Adults
- Conditions
- Rabies
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- CureVac
- Target Recruit Count
- 101
- Registration Number
- NCT02241135
- Locations
- 🇩🇪
Abteilung für Infektions- und Tropenmedizin der Ludwig-Maximilians-Universität, Munich, Germany
Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
- Conditions
- Rabies
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- CureVac
- Target Recruit Count
- 72
- Registration Number
- NCT02238756
- Locations
- 🇩🇪
CRS Clinical Research Services Mönchengladbach GmbH, Mönchengladbach, Germany
An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer
- Conditions
- Prostate Carcinoma
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- CureVac
- Target Recruit Count
- 35
- Registration Number
- NCT02140138
- Locations
- 🇩🇪
Nationales Zentrum für Tumorerkrankungen, Medizinische Onkologie, Heidelberg, Baden-Württemberg, Germany
🇩🇪Klinik für Urologie, Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany
🇩🇪Klinikum rechts der Isar, Urologische Klinik und Poliklinik der Technischen Universität München, München, Bayern, Germany
Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Carcinoma
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- CureVac
- Target Recruit Count
- 26
- Registration Number
- NCT01915524
- Locations
- 🇦🇹
Innsbruck Medical University, Department of Internal Medicine V (Hematology and Oncology), Innsbruck, Austria
🇩🇪HELIOS Klinikum Emil von Behring GmbH, Berlin, Germany
🇩🇪Augusta-Kranken-Anstalt gGmbH, Bochum, Germany
Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2013-03-25
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- CureVac
- Target Recruit Count
- 197
- Registration Number
- NCT01817738
- Locations
- 🇨🇿
Krajská zdravotní, a.s. - Nemocnice Chomutov, o.z.Onkologické oddělení, Chomutov, Czech Republic
🇨🇿Fakultní nemocnice Olomouc, Urologická klinika, Olomouc, Czech Republic
🇨🇿Multiscan, a.s, Oddělení klinické a radiační onkologie, Pardubice, Czech Republic
Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- CureVac
- Target Recruit Count
- 46
- Registration Number
- NCT00923312
- Locations
- 🇩🇪
RWTH Aachen, Aachen, Germany
🇩🇪Medizinische Klinik III, Universitätsklinikum Bonn, Bonn, Germany
🇩🇪Medizinische Klinik V, Klinikum Darmstadt, Darmstadt, Germany
Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease
- Conditions
- Hormonal Refractory Prostate Cancer
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- CureVac
- Target Recruit Count
- 48
- Registration Number
- NCT00831467
- Locations
- 🇩🇪
Universitätsklinikum Aachen, Urologische Klinik, Aachen, Germany
🇩🇪Charité Universitätsmedizin Berlin, Urologische Klinik u. Hochschulambulanz, Berlin, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus der TU Dresden, Klinik und Poliklinik für Urologie, Dresden, Germany